<DOC>
	<DOCNO>NCT01515410</DOCNO>
	<brief_summary>The primary objective study explore efficacy tolerability DM-1992 compare standard carbidopa/Levodopa Immediate-Release ( CD/LD IR ) tablet ( Sinemet IR ) measure : - `` ON '' time dyskinesia non-troublesome dyskinesia - `` OFF '' time</brief_summary>
	<brief_title>Study Advanced Parkinson 's Disease Patients With Predictable Motor Fluctuations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>1 . Men woman least 30 year old time inform consent advance idiopathic Parkinson 's disease predictable wearingoff motor fluctuation Hoehn Yahr Stage IIIII `` . '' 2 . Patients able differentiate `` ON '' `` OFF '' state average daily `` OFF '' time ≥ 2.5 hour study entry . 3 . On stable daily dose LD ≥ 400 mg ≤1600 mg least 1 month prior screen visit . 4 . Non CD/LD contain antiParkinson 's medication keep stable dos 1 month prior screen visit . Patients willing keep non LD contain medication consistently throughout study duration . 5 . Female patient childbearing potential abstinent continue practice willing continue throughout study appropriate contraceptive ( define Nova ring , oral , injected , transdermal patch , implant , barrier ) . 6 . Mini Mental State Examination ( MMSE ) ≥ 26 screen visit . 7 . Able provide inform consent willing sign Health Insurance Portability Accountability Act ( HIPAA ) authorization . 8 . Able willing comply protocol , include availability schedule study visit blood sample collection . Must observation competent care giver throughout study participation . 1 . Patients atypical druginduced Parkinson 's disease . 2 . Patients known history hypersensitivity levodopa carbidopa . 3 . Patients receive treatment dopamine receptor block agent 4 . Patients history seizure except childhood febrile seizure . 5 . Patients dementia . 6 . Patients significant history GI diseases ( severe inflammatory bowel disease , irritable bowel disease , dyspepsia , gastroesophageal reflux disease etc . ) past five year . 7 . Patients history gastric surgery vagotomy pyloroplasty . 8 . Patients immunecompromised state . 9 . Patients clinically significant hepatic insufficiency ChildPugh total score ≥ 5 . 10 . Patients calculate creatinine clearance ( Clcr ) &lt; 50 mL/min use CockcroftGault equation . 11 . Patients difficulty swallow tablet . 12 . Patient participate clinical trial investigational drug device within 30 day screen visit . 13 . Patients serious medical condition , opinion Investigator would jeopardize safety patient affect validity study result .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>PD</keyword>
	<keyword>stage2/3Parkinson 's</keyword>
	<keyword>Advanced Parkinson 's Disease Motor Fluctuations</keyword>
</DOC>